Dr. Agarwal's Health Care reports FY26 revenue of over ₹2,000 cr
The company confirms FY26 growth targets with plans to add 60 new facilities in FY27 at a cost of up to ₹400 cr.
— 1 earlier story on Dr. Agarwal's Health Care Ltd. →What's new with Dr. Agarwal's Health Care Ltd.
- The concall summary recaps FY26 results with revenue growth of 20.9% and PAT growth of 52.4%.
- Management plans to add 60 new facilities in FY27.
- Capex for FY27 is projected between ₹380 cr and ₹400 cr, with EBITDA margins seen at 28-30%.
Why this matters for Dr. Agarwal's Health Care Ltd.
The conference call confirms the financial trajectory and expansion plans already communicated in previous disclosures. No new material information emerged from the discussion.
What we're watching
- Execution of the 60-facility expansion plan in FY27.
- Consistency of EBITDA margins within the 28-30% range.
- Actual deployment of the projected ₹380-400 cr capex.
The full read
Dr. Agarwal's Health Care closed FY26 with revenue topping **₹2,000 crore**, representing a **20.9%** increase over the previous year. Profit after tax grew by **52.4%** as the company maintained its expansion pace. Management used the earnings call to reconfirm the outlook for FY27, which includes opening **60** new facilities supported by a capital expenditure budget of **₹380 crore** to **₹400 crore**. The company anticipates EBITDA margins will remain steady between **28%** and **30%**. Because these details were already contained in prior filings, the call provides no new market-moving data. It serves merely as a formal walkthrough of results already priced into the equity.
Questions answered
- Did the conference call disclose any new financial data?
- No. The filing is a summary of previously disclosed earnings and expansion plans.